肝性脑病:当前与新兴治疗方式
肝性脑病是肝硬化可逆的神经认知并发症,至少30%肝硬化患者发生。氨被认为是肝性脑病发展的元凶,现有获批治疗多通过作用于该毒素促进缓解。本文综述当前已接受的治疗、新型可用疗法及未来治疗方式。
要点
- 肝性脑病是肝硬化可逆的神经认知并发症,至少30%肝硬化患者发生。
- 氨被认为是肝性脑病发展的元凶,现有获批治疗多作用于该毒素。
- 本文综述当前已接受治疗、新型可用疗法及未来治疗方式。
核心结论
- 氨被认为是肝性脑病发展的元凶,现有获批治疗多通过作用于该毒素帮助缓解肝性脑病。
研究设计与样本
- 本文为综述,概述肝性脑病特征与病理生理后,探讨当前已接受的治疗、新型可用疗法及未来治疗方式。
主要发现
- 肝性脑病是肝硬化可逆的神经认知并发症,至少30%肝硬化患者发生。
- 肝性脑病对照护者和医疗系统造成显著经济负担。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic encephalopathy (HE) is a potentially reversible neurocognitive complication of cirrhosis. It has been reported in at least 30% of patients with cirrhosis and imposes a significant economic burden on caregivers and the healthcare system. Ammonia has been recognized as the culprit in HE development, and all the currently approved treatments mostly act on this toxin to help with HE resolution. After a brief overview of HE characteristics and pathophysiology, this review explores the current accepted treatments for this debilitating complication of cirrhosis. This is followed by an overview of the novel available therapies and a brief focus on future treatment modalities for HE.
引用
- Fallahzadeh MA, Rahimi RS. Hepatic Encephalopathy: Current and Emerging Treatment Modalities. Clin Gastroenterol Hepatol. 2022. PMID: 35940731. doi:10.1016/j.cgh.2022.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。